Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial

The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived “alarmin.” Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2. Approved biol...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of allergy and clinical immunology Ročník 148; číslo 3; s. 790 - 798
Hlavní autori:	Kelsen, Steven G., Agache, Ioana O., Soong, Weily, Israel, Elliot, Chupp, Geoffrey L., Cheung, Dorothy S., Theess, Wiebke, Yang, Xiaoying, Staton, Tracy L., Choy, David F., Fong, Alice, Dash, Ajit, Dolton, Michael, Pappu, Rajita, Brightling, Christopher E.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.09.2021
Predmet:	asthma exacerbations eosinophils IL-33 severe asthma ST2 ST2 asthma exacerbations Feno AE SAE severe asthma ICS eosinophils IL-33 AER T2
ISSN:	0091-6749, 1097-6825, 1097-6825
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!